What are fibroblast growth factor‑23 (FGF‑23) levels in primary hyperparathyroidism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FGF-23 Levels in Primary Hyperparathyroidism

FGF-23 levels are elevated in primary hyperparathyroidism (PHPT), typically ranging from 45-77 pg/mL compared to normal controls at approximately 29-50 pg/mL, and these levels decrease after successful parathyroidectomy. 1, 2, 3

The Evidence Pattern

Multiple studies consistently demonstrate that FGF-23 is increased in PHPT patients:

  • In hypercalcemic PHPT: FGF-23 levels average 77 ± 33 pg/mL 1 and 50.8 ± 6.1 pg/mL 3, significantly higher than controls
  • In normocalcemic PHPT: FGF-23 levels are intermediate at 59.5 ± 23 pg/mL, suggesting this represents an early stage of disease progression 1
  • Post-parathyroidectomy: FGF-23 decreases from median 45.2 pg/mL to 36.8 pg/mL after surgical cure 2

Regulatory Mechanism

The elevation of FGF-23 in PHPT appears to be primarily calcium-driven rather than PTH-driven:

  • Serum calcium is an independent predictor of FGF-23 levels in multivariate analysis 4, 5
  • FGF-23 drops rapidly after parathyroidectomy, following the decrease in calcium levels within hours 4
  • The parathyroid glands themselves do not produce FGF-23 (confirmed by absence of Fgf23 expression in resected adenomas) 4

The physiological interpretation: FGF-23 elevation represents an adaptive counter-regulatory mechanism attempting to oppose PTH's stimulation of 1,25(OH)₂D production 3. The stronger negative correlation between FGF-23 and 1,25(OH)₂D in PHPT patients (r=-0.674) compared to cured patients (r=-0.509) supports this compensatory role 3.

Clinical Correlations

FGF-23 levels in PHPT correlate with:

  • Positive correlations: Serum calcium, intact PTH, adenoma weight, body mass index, triglycerides, and insulin levels 2, 3, 4, 5
  • Negative correlations: Creatinine clearance, serum phosphate, and 1,25(OH)₂D 3, 4, 5

Important Caveats

Renal function matters: In PHPT patients with normal renal function (creatinine clearance ≥70 mL/min), FGF-23 levels may not differ significantly from healthy controls 5. The elevation becomes more pronounced with declining renal function, as creatinine clearance is an independent predictor of FGF-23 levels 4, 5.

Differential diagnosis consideration: When evaluating hypophosphatemia in suspected PHPT, markedly elevated FGF-23 should prompt consideration of genetic hypophosphatemic disorders (like X-linked hypophosphatemia) where FGF-23 excess is the primary pathology rather than a secondary response 6.

Prognostic Implications

Higher FGF-23 levels associate with cardiovascular risk, particularly nighttime blood pressure elevation (r=0.31), though PTH remains the independent predictor after multivariate adjustment 2. The metabolic risk profile (insulin resistance, dyslipidemia) also tracks with FGF-23 elevation 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.